An interventional study of Prophylactic sac filling with AneuFix in Abdominal Aortic Aneurysm and Endoleak, sponsored by TripleMed B.V.. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-07.
Sponsored by TripleMed B.V. · Not applicable, Interventional, and Treatment
This study is set up to assess the feasibility and safety of the clinical procedure using AneuFix in a prophylactic setting at the time of EVAR endograft implantation.
The investigational device is called ANEUFIX, which is a product treating the endoleak by blockage of backflowing blood vessels, i.e. by filling the endoleak void and nidus of feeding artery and exit of existing draining arteries.
ANEUFIX is a polymer that cures rapidly (2-4 min at 37°C) after injection into the AAA-sac close to the nidus.
Asymptomatic, infrarenal AAA that requires surgery with a high-risk profile of developing endoleak type II in line with the recommendations of Guntner et al:
Exclusion Criteria:
Device: ANEUFIX
Device: Prophylactic sac filling with AneuFix
ANEUFIX is administered by injection into the AAA via transferal access at the time of EVAR placement using imaging techniques to guide the place of injection.
Technical Success
Technical Success as demonstrated by the feasibility to fill the AAA sac after EVAR during the same procedure, and by the rate of (all) endoleaks after EVAR followed by the AneuFix procedure
Time frame: 24 hours
Clinical Success rate
Clinical Success as demonstrated by the occurrence of type II endoleaks at 6 months after EVAR, and aneurysmal sac growth at 6 months after EVAR
Time frame: 6 months
Clinical Success rate
Clinical Success as demonstrated by the occurrence of type II endoleaks at 12 months after EVAR, and aneurysmal sac growth at 12 months after EVAR
Time frame: 12 months
Intraoperative occurrence of complications
Adverse events occurring during the surgical intervention are registered.
Time frame: 24 hours
Peri-operative complications
Rate of peri-operative complications
Time frame: 30 days
Prevention of (any type of) endoleak
Occurrence of (any type of) endoleak
Time frame: 1, 6 and 12 months
adverse events
Occurrence of adverse events and adverse device effects
Time frame: 1, 6 and 12 months
Re-interventions
Rate of secondary endovascular or surgical re-interventions
Time frame: 1, 6 and 12 months
Aneurysm rupture
Rate of aneurysm rupture
Time frame: 6 and 12 months
Proportion of patients surviving 24 months after treatment
Survival throughout the study up until 24 months
Time frame: 24 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TripleMed B.V.